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Aim: Investigating vitamin D and parathormone (PTH) concentrations as predictors of the devel-
opment and severity of diabetic retinopathy.
Methods: Two hundred diabetic patients presenting with suspected diabetic retinopathy were
investigated, levels of vitamin D [25(OH) D3 and Calcitriol] and PTH were measured. Diabetic ret-
inopathy was assessed using 7-ﬁeld stereoscopic Fundus photography.
Results: Mean serum concentration of 1, 25 dihydroxy vitamin D 3 (1, 25(OH) 2 D3) was signif-
icantly lower in diabetic subjects with retinopathy than in diabetic subjects with no retinopathy and
there is a signiﬁcant negative correlation between the mean level of 1, 25(OH) 2 D3 and the degree
of severity of retinopathy. Level of PTH was signiﬁcantly higher in severe NPDR and PDR com-
pared to patients with no retinopathy.
Conclusions: Low levels of vitamin D might be a risk marker of development or progression of
diabetic retinopathy. It might be advisable that detailed ophthalmologic examination is neededing Faisal Specialist Hospital
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120 Rania Naguib Abdel Mouteleb Abdel Reheem, Maaly Abdel Halim Mohamed Abdel Fattahfor diabetics whose serum 1, 25(OH) 2D3 concentrations gradually decreased. The measurement of
serum 1, 25(OH) 2 D3 concentrations could become a useful biochemical means to predict the
severity of DR in patients with diabetes mellitus.
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reserved.1. Introduction
Diabetic retinopathy (DR) is one of the most common causes
of blindness in individuals between the ages of 20 and 65 years.
Neovascularization is the hallmark of proliferative diabetic
retinopathy (PDR). Development and progression of diabetic
microangiopathy in terms of retinopathy are known to be clo-
sely related to poor metabolic control, elevated arterial blood
pressure, and other risk factors.1,2
Vitamin D (VD) is necessary for normal insulin release and
maintenance of glucose tolerance. It increases insulin sensitiv-
ity and insulin secretion.3
The b (beta) cell possesses speciﬁc receptors for the acti-
vated hormone 1, 25-dihydroxyvitamin D3 (1, 25(OH) 2 D3)
and vitamin D-dependent calcium-binding proteins.4 Insulin
secretion is impaired by vitamin D deﬁciency and restored by
1, 25(OH) 2 D3 administration.5
In addition to its osteocalcic effect, VD has immunomodu-
latory, anti-inﬂammatory, antioxidant, antiangiogenic, and
antiproliferative functions in many kinds of cell. All of them
are mediated by vitamin D receptors (VDR), a member of
the nuclear receptor super family, which is extensively ex-
pressed in the retina.6
In a mouse model of ischemic retinopathy, 1, 25(OH) 2 D3
inhibited retinal neovascularization,7 while in cell culture, it
inhibited endothelial cell proliferation.8 The antitumor activity
of vitamin D compounds has been demonstrated against a
variety of cancers, including retinoblastoma.9,10
It also reduces corneal inﬂammation and neovasculariza-
tion.11–13 The reduced vascularity observed in many
tumors treated with vitamin D compounds suggests tumor vas-
culature may be a target.7 Therefore, low serum levels of 1,
25(OH) 2 D3 may lead to increased, uncontrolled angio-
genesis.14 And may be associated with endothelial dys-
function.15
Vitamin D deﬁciency is also associated with a high plasma
PTH levels which is present in sub retinal ﬂuids of the human
eye. PTH excess can reduce glucose tolerance16 and induce
inﬂammatory cytokines.17
Vitamin D may confer its actions via inhibition of inﬂam-
mation, down regulation of the renin–angiotensin system, im-
proved insulin secretion, and an antiproliferative effect on
endothelial cells.18
In the present study, we investigate vitamin D and para-
thormone (PTH) concentrations as predictors of the develop-
ment and severity of diabetic retinopathy.
2. Materials and methods
2.1. Patients
The present study is a cross sectional study with informed con-
sent signed by all patients according to a protocol approved by
the Ethics Committee of the Hospital.Our study sample comprised 200 diabetic patients present-
ing with suspected diabetic retinopathy admitted to Alexandria
and kasr Al Eini hospital. Forty-three patients were insulin-
dependent (type 1 diabetes) and 157 were noninsulin depen-
dent (type 2 diabetes).
The duration of diabetes ranged from 11 to 28 years with a
mean range of 19.6 ± 1.7 years. Fifty-two percentage were fe-
males while 48% were males with a mean age of
69 ± 2.6 years.
Therapy modalities for type 2 diabetes were diet therapy
alone (5%), diet therapy plus oral antidiabetic drugs (74%)
or diet therapy plus insulin therapy (21%).
History taking and complete clinical examination were
done and recorded. Patients receiving Vit D therapy or similar
drugs as mineral supplements or medications that are known
to alter mineral metabolism (e.g., estrogen, thiazide diuretics,
and anticonvulsants) were excluded from the study. Patients
with major medical illness including renal failure, hepatic dis-
ease, and skeletal disease were also excluded.
2.2. Sampling
Blood samples were collected after an overnight fast. Serum
was separated and stored frozen at 20 C. Routine blood
examination, HbA (1c) were measured by using commercially
available kits.
Levels of vitamin D [25(OH) D3 and Calcitriol] were deter-
mined by ELISA Kit from DRG International, Inc. – Biocom-
pare Buyer’s and PTH levels by ELISA immunodiagnostic
system (IDS).
2.3. Ophthalmological examination
Assessment of visual acuity (Best Corrected Visual Acuity)
(BCA) and anterior segment examination by slit lamp biomi-
croscopy were performed.
Diabetic retinopathy was assessed using 7-ﬁeld stereoscopic
fundus photography. Fundus ﬂuorescein angiography was per-
formed for all patients with retinopathy.
Levels of retinopathy were classiﬁed according to early
treatment diabetic retinopathy study (ETDRS) into: No reti-
nopathy (NR), mild nonproliferative diabetic retinopathy
(mild NPDR), moderate nonproliferative diabetic retinopathy
(moderate NPDR), severe nonproliferative diabetic retinopa-
thy (severe NPDR) and proliferative diabetic retinopathy
(PDR) Table 1.
(Twenty-one percentage) of our patients had NR, (19%)
had mild NPDR, (17.5%) had moderate NPDR, (20.5%)
had severe or very severe NPDR and 22% had PDR.
2.4. Statistical analysis
Data were collected, tabulated and then analyzed using SPSS
Ver.17. Qualitative data were presented as numbers and per-
Table 1 Classiﬁcation of diabetic retinopathy.
Nonproliferative Diabetic Retinopathy (NPDR)
A. Mild NPDR
 At least one microaneurysm
B. Moderate NPDR
 Hemorrhages or microaneurysms (H/Ma)
 Soft exudates, Venous beading (VB), and intraretinal
microvascular abnormalities (IRMAs) deﬁnitely present.
C. Severe NPDR
 H/Ma in all 4 quadrants
 VB in 2 or more quadrants
 IRMA in at least 1 quadrant
D. Very Severe NPDR
 Any two or more of C
Proliferative Diabetic Retinopathy
E. Early PDR
 New vessels on the retina
 Deﬁnition not met for F
F. High-Risk PDR
 New vessels on the disc (NVD) of 1/4 to 1/3 or more of the disc
area or
 Any NV and vitreous, preretinal or vitreous hemorrhage
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deviation. ANOVA test was used for comparison between the
means of quantitative variables, with post hoc tests for paired
comparisons. Spearman’s correlation coefﬁcient by rank was
used to analyze correlations between different parameters. A
5% level was chosen as a level of signiﬁcance in all statistical
tests used in the study.
3. Results
Mean serum concentration of 1, 25 dihydroxy vitamin D 3 (1,
25(OH) 2 D3) was signiﬁcantly lower in diabetic patients withTable 2 Correlation between the mean level of 1, 25(OH) 2 D3 an
Degree of retinopathy Mean level of 1,
Mild NPDR 67.4 ± 13.7
Moderate NPDR 59.3 ± 11.2
Severe NPDR 45.7 ± 16.6
PDR 34.1 ± 17.2
Mild NPDR): mild nonproliferative diabetic retinopathy.
(Moderate NPDR): moderate nonproliferative diabetic retinopathy.
(Severe NPDR): severe nonproliferative diabetic retinopathy.
(PDR): proliferative diabetic retinopathy.
p value < 0.05 is signiﬁcant.
Table 3 Correlation between the Mean serum concentration of 1
retinopathy and different parameters.
Age
r p
Mean serum concentration of (1, 25(OH) 2 D3) 0.154 <0
The degree of retinopathy 0.108 0
p value < 0.05 is signiﬁcant.retinopathy than those with no retinopathy (NR)
(51.4 ± 16.64 vs. 70.7 ± 15.56 pmol/L, p< 0.001). There
was a signiﬁcant negative correlation between the mean level
of 1, 25(OH) 2 D3 and the degree of severity of retinopathy
(p< 0.001). In mild nonproliferative diabetic retinopathy
(mild NPDR), the level was 67.4 ± 13.7 pmol/L. In moderate
nonproliferative diabetic retinopathy (moderate NPDR) the
level was 59.3 ± 11.2 pmol/L. In severe nonproliferative dia-
betic retinopathy (severe NPDR) it was 45.7 ± 16.6 pmol/L
and in proliferative diabetic retinopathy (PDR) it was
34.1 ± 17.2 pmol/L (Table 2).
There was a signiﬁcant negative correlation between the
Mean serum concentration of 1, 25 dihydroxy vitamin D 3
(1, 25(OH) 2 D3) and the age (r= 0.154, p< 0.001), dura-
tion of diabetes (r= 0.342, p < 0.05), and HbA1c
(r= 0.177, p< 0.001). The latter 3 parameters showed a sig-
niﬁcant positive correlation with the degree of retinopathy
(r= 0.108, p = 0.016) (r= 0.217, p < 0.05) and (r= 0.365,
p< 0.001) respectively (Table 3). There was no correlation be-
tween serum level of 1, 25 dihydroxy vitamin D 3 (1, 25(OH) 2
D3) or the degree of retinopathy with the modality of treat-
ment among different groups (p> 0.05).
The mean serum concentration of 25(OH) D was
31.6 ± 12.01 nmol/L. There was no correlation between serum
25(OH) D and mean serum level of 1, 25 dihydroxy vitamin D
3 or the degree of retinopathy (p> 0.05).
In diabetic patients with no retinopathy (NR), the mean ser-
um concentration of PTH was 3.1 ± 0.45, 3.2 ± 0.6 pmol/L in
mild nonproliferative diabetic retinopathy (mild NPDR),
3.4 ± 0.17 pmol/L in moderate nonproliferative diabetic reti-
nopathy (moderate NPDR), 5.4 ± 1.0 pmol/L in severe non-
proliferative diabetic retinopathy (severe NPDR) and
6.0 ± 0.3 pmol/L in proliferative diabetic retinopathy (PDR).
There was no correlation between the mean serum concen-
tration of PTH and the degree of retinopathy in NR, mild
NPDR moderate NPDR (p> 0.05) while the level of PTHd the degree of severity of retinopathy.
25(OH) 2 D3 (pmol/L) P value
(p< 0.001)
(p< 0.001)
(p< 0.001)
(p< 0.001)
, 25 dihydroxy vitamin D 3 (1, 25(OH) 2 D3), the degree of
Duration of diabetes HbA1c
r p r p
.001 0.342 <0.05 0.177 <0.001
.016 0.217 <0.05 0.365 <0.001
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to patients with no retinopathy (NR) (p< 0.001).
4. Discussion
Calcitriol (1a, 25-dihydroxyvitamin D3), the active hormonal
form of vitamin D has a very important role, both pharmaco-
logical and physiological, at cellular level. It is a potent osteo-
calcic, immunomodulatory, anti-inﬂammatory and
antioxidant factor in many kinds of cells. It also increases insu-
lin sensitivity and insulin secretion.3
A majority of studies on the effect of 1, 25(OH) 2D3 on cell
growth and differentiation report an inhibition of proliferation
coupled with an induction of differentiation.19
In addition to its effects on tumor cell proliferation and dif-
ferentiation, it has a potent inhibitory effect on angiogenesis.10
Biological models support a causal role for VDD in prolif-
erative retinopathy, which is characterized by neovasculariza-
tion and angiogenesis. Higher serum 1, 25(OH) 2 D3 was
associated with reduced angiogenesis in both a transgenic ret-
inoblastoma model and ischemic retinopathy in mice.7
Mantell et al.19 demonstrated that the antiangiogenic prop-
erties of 1, 25(OH) 2 D3 are mediated by a direct effect on
endothelial cells through inhibition of endothelial cell sprout-
ing and morphogenesis, inhibition of VEGF-induced endothe-
lial cell proliferation, inducing the regression of existing
endothelial cell sprouts and elongated cells and inhibiting the
formation of new blood vessels in tumor xenografts.
1, 25(OH) 2 D3 also inhibits vascular endothelial growth
factor (VEGF) induced endothelial cell proliferation,19
down-regulates the IGF-I pathway,20 up-regulates the cellular
transporters of sulfate21 which are negative regulators of angi-
ogenesis,22 down-regulates the renin–angiotensin system,23
stimulates the TGFb-1 (an antiproliferative and proapoptotic
molecule),24 and inhibits multiple proinﬂammatory and proan-
giogenic cytokines.11–13 All of these molecules have been impli-
cated in the pathogenesis of DR. On the other hand, calcium
homeostasis and calcium-dependent signaling pathways have
an important role in the development of retinal hypoxia, a ma-
jor process in severe DR.6
Therefore, low serum levels of 1, 25(OH) 2 D3 may have an
association with increased, uncontrolled angiogenesis with the
progression of DR.25
Our study showed that the Mean serum concentration of 1,
25 dihydroxy vitamin D 3 (1, 25(OH) 2 D3) was signiﬁcantly
lower in diabetic subjects with retinopathy than in diabetic
subjects with no retinopathy (NR).
Also there was a signiﬁcant negative correlation between
the mean level of 1, 25(OH) 2 D3 and the severity of retinop-
athy being the lowest in proliferative diabetic retinopathy
(PDR) group suggesting that neovascularization in the retina
may involve a decrease in serum 1, 25(OH) 2 D3 concentra-
tions in patients with DR.
These ﬁndings were in agreement with the study done in
2000 by Hulya et al.25 who investigated whether there is a rela-
tionship between serum 1, 25 dihydroxy vitamin D3 [1, 25(OH)
2 D3] and severity of diabetic retinopathy. They concluded
that there was an inverse relationship between the severity of
the retinopathy, i.e., neovascularization, and serum 1,
25(OH) 2 D3 concentrations, being the lowest in PDR and
the highest in diabetic patients without retinopathy (NDR).The current ﬁnding may suggest a permissive role of vitamin
D deﬁciency in the pathogenesis of DR.
Our study revealed no correlation between the mean serum
25(OH) D and the degree of retinopathy. These results are in
agreement with Hu¨lya Aksoy.25 While a cross-sectional study
of 581 type 2 diabetic patients shows a signiﬁcant association
between the existence of proliferative retinopathy and a de-
crease in 25(OH) D3. Also, investigators found a decrease in
25(OH) D3 according to the number of micro vascular compli-
cations present.26,27
A clinic-based, cross-sectional study was conducted by
Paynes and his colleagues in 2011 to assess the relationship be-
tween vitamin D status and diabetic retinopathy. They con-
cluded that diabetic subjects, especially those with PDR,
have lowered 25(OH) D levels than those without diabetes.28
The mean serum level of PTH in our study was signiﬁcantly
higher in severe NPDR and PDR compared to patients with
no retinopathy (NR). These results are in agreement with the
ﬁndings of previous studies.6,26,29
This ﬁnding may be explained by a compensatory mecha-
nism to the low serum 1, 25(OH) 2 D3 concentrations.
PTH excess can induce inﬂammatory cytokines which may
play a role in the pathogenesis of proliferative DR.6,17
From the results of the present study we can conclude that
low levels of vitamin D might be a risk marker of development
or progression of diabetic retinopathy. It might be advisable
that detailed ophthalmologic examination is needed for diabet-
ics whose serum 1, 25(OH) 2 D3 concentrations are dimin-
ished. The measurement of serum 1, 25(OH) 2 D3
concentrations could become a useful biochemical means to
predict the severity of DR in patients with diabetes mellitus.Acknowledgement
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